Close Menu

protein biomarkers

Scienion will produce protein microarray batches of more than 1,000 arrays for Protagen for the clinical validation of biomarker panels.

Under the terms of an agreement, Protagen's UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS.

The firms will co-develop a new tissue-based imaging and analysis solutions for protein biomarkers.

Pronota will use its MASStermind platform for the discovery stage of the deal, and its MASSterclass technology for the verification work.

The partners will use Aushon's technology to develop predictive diagnostic markers for liver metastases of colorectal cancer.

The discovery is the first milestone of a program by the partners to develop a panel of protein biomarkers they plan to use in clinical trials to develop treatments for the disease.

Under the terms of the agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally. Additional terms of the deal were not disclosed.

The company said that it will work with BMS to investigate the utility of its technology for diagnosis of Alzheimer's disease and for identifying individuals with early-stage cognitive impairment that are likely to progress to Alzheimer's disease.

Under its contract with SAIC-Frederick, Epitomics will develop high affinity and renewable agents to capture tryptic peptides derived from human plasma protein biomarkers.

Seoul Clinical Laboratories will distribute the firm's OvPlex diagnostic panel in South Korea after the firm received market clearance from the South Korea Food and Drug Administration.

Pages

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.